Clinical Trials Logo

Clinical Trial Summary

This clinical trial studies the effectiveness of narrow margins in patients with low-risk basal cell carcinoma undergoing surgery to remove skin lesions on the face. A margin is the area of normal tissue around a tumor taken out during surgery to make sure all of the cancer is removed. This clinical trial studies tissue samples to determine the least amount of tissue that must be removed to give an acceptable cure rate. This may allow less normal tissue to be removed from patients and may be a less expensive surgery.


Clinical Trial Description

PRIMARY OBJECTIVES:

I. To determine the success rate of narrow margin excisions of low-risk facial basal cell carcinoma (BCC).

SECONDARY OBJECTIVES:

I. To determine the narrowest excision margin for low-risk facial BCC that gives an acceptable (95%) cure rate over a 3 year follow-up period. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02579551
Study type Interventional
Source Thomas Jefferson University
Contact
Status Completed
Phase N/A
Start date December 7, 2011
Completion date May 4, 2017

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02978625 - Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Phase 2
Completed NCT02735356 - Topical Itraconazole in Treating Patients With Basal Cell Cancer Early Phase 1
Completed NCT03180528 - Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer Phase 2
Completed NCT02690948 - Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer Phase 1/Phase 2
Withdrawn NCT02699723 - Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer Early Phase 1